Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Free Thinking: Biosimilars: Friend or foe to healthcare?

July 9, 2014 | Market Access, Rob White, biosimilars, therapy watch 

Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.

Biologics, whose active substance is derived from a living organism, have enabled healthcare to make significant therapeutic advances across a whole raft of therapy areas since their introduction in the 1970s. However, these medicines come at a price, reflecting the complexities involved in developing and manufacturing products derived from living cells. Annual treatment costs in the US can range from US$25,000 to US$200,000.

Biosimilars medicines, the follow-on “generics” to biologics which have come off-patent, present a significant opportunity to introduce cutting-edge therapies to the treatment landscape for many diseases, while also addressing the cost-effectiveness demands now being made on global healthcare systems. 

Download and read the complimentary whitepaper at http://bit.ly/1Gmknh7  

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges.

This content was provided by Research Partnership

Company Details

- PMLiVE

Research Partnership

Email
Website

 Latest Content from  Research Partnership 

Patient Power: Too Much of a Good Thing?

Mary Assimakopoulos, reveals findings from the company’s Therapy Watch market research data, investigating patient behaviour in Crohn’s Disease and discusses how pharma can benefit from improved patient understanding

Webinar: Mobile Research in Asia and Emerging Markets

Current statistics around mobile technology reveal that many physicians in Asia are now using smartphones, tablets and other mobile devices to assist them in their daily practices. In China alone,73%...

Webinar: Understanding the Patient Journey in Order to Influence Prescribing Decisions

Using real data, this webinar looks at the increasingly popular view that says we need to understand more about the patient and the relationship they have with their physicians in...

Webinar: Focus on China: Conducting Research in the World’s Fastest Growing Pharma Market

This webinar looks to provide market research professionals with an overview of the Chinese healthcare market and provide participants with top tips for conducting relevant and effective market research in...

Webinar: Prescription Rationale: Physician Research via an iPhone App

This webinar explores the potential of using smartphone Apps as a platform for collecting detailed qualitative insights into physicians' decision rationale at the moment of prescription.

Maximising patient adherence by leveraging the patient/ physician/ pharma relationship

Director Marc Yates looks at the problem of patient compliance - can a better understanding of patient attitudes, needs and behaviours help pharma develop strategies to improve adherence?

Digital research in Asia

Director Marc Yates uses findings from a study conducted in six markets in Asia to explore how digital channels are being utilised by consumers and look at the digital opportunities...

Achieving customer centricity – Using immersion techniques to get closer to the pulse of the customer

Director Marc Yates discusses the importance of being customer-centric in the pharmaceutical industry and how immersion techniques in market research can help develop a better understanding of the customer.

The Mobile Revolution – Using mobile Apps to deliver “in-the-moment” market research to global healthcare

Director John Branston investigates the use of mobile research in order to capture immediate detailed, qualitative insights into prescription rationale at the patient level.